Latest Regulatory Filings News

Tlou Energy has admitted to a late filing of a key director interest notice for its former Managing Director, prompting an ASX inquiry into its compliance processes. The company vows to tighten internal controls following the breach.

West Cobar Metals has initiated approvals for a 5,000m air core drilling campaign at its promising Mystique Gold Project, aiming to unlock significant gold mineralisation in Western Australia’s Fraser Range.

Optiscan Imaging Ltd has commenced a landmark clinical study at Royal Melbourne Hospital, testing its cutting-edge InVue® and InForm™ devices to improve breast cancer surgery precision. The study aims to generate critical data for US FDA approval and could redefine surgical oncology workflows.

Cambium Bio has secured ethics approvals in Australia and the US to initiate pivotal Phase 3 trials of Elate Ocular, targeting moderate to severe dry eye disease, with patient dosing expected in October 2025.

Dimerix Limited has received a significant milestone payment from its Japanese partner FUSO Pharmaceutical, marking progress in the Phase 3 clinical trial of DMX-200 for kidney disease. This payment underscores the growing momentum behind Dimerix’s global licensing strategy.

LTR Pharma has successfully completed the extractables study for its intranasal erectile dysfunction spray SPONTAN, confirming safety compliance and initiating the next phase of leachables testing to support FDA approval.

First Au Limited has completed the initial tranche of its $1.5 million private placement, issuing over 4 million shares, while the much larger second tranche awaits shareholder approval at the upcoming AGM.

Electro Optic Systems Holdings Limited has explained a delayed filing of a director interest notice as an administrative oversight, affirming its compliance processes remain robust.

Cleo Diagnostics has gained approval to access the prestigious PLCO biobank, a move set to strengthen its FDA submission and accelerate development of its ovarian cancer diagnostic tests.

Solis Minerals has voluntarily delisted from the TSX Venture Exchange to concentrate on its primary ASX listing, prompting changes to its ASX waivers and financial reporting calendar.

North Stawell Minerals has completed a $1 million placement, issuing over 33 million shares to fund its exploration efforts in Victoria's Stawell Mineralised Corridor.

Rhythm Biosciences has regained NATA accreditation for its geneType laboratory, a key step toward commercialising its ColoSTAT® cancer risk test as an in-house diagnostic.